21-hydroxylase deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
The hormonal responses to ACTH of the family members with cryptic 21-hydroxylase deficiency were determined and compared to the responses of patients with CAH, patients with acquired adrenal hyperplasia, family members predicted to be heterozygous for CAH, family members predicted to be unaffected, and the general population.
|
6271801 |
1981 |
21-hydroxylase deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
A modified short ACTH test for the detection of heterozygote carriers of 21-hydroxylase deficiency (21-OHD) was applied to twenty-one controls and fourteen parents of children with 21-OHD.
|
6249520 |
1980 |
21-hydroxylase deficiency
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
HLA typing and ACTH testing of her parents and siblings provided evidence of a linkage between HLA and 21-hydroxylase deficiency loci.
|
6251108 |
1980 |
21-hydroxylase deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Lack of ACTH and androgen receptor expression in a giant adrenal myelolipoma associated with 21-hydroxylase deficiency.
|
18618087 |
2008 |
21-hydroxylase deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genotyping more patients with nonclassical 21-hydroxylase deficiency will help to redefine the cut-off value for ACTH-stimulated 17OH-P for correct diagnosis of this disease.
|
10792340 |
2000 |
21-hydroxylase deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
An ACTH stimulation test in which serum hormone concentrations of 17-OHP, Delta(4)-androstenedione, and testosterone are determined will assist in the diagnosis of NC 21-OHD, but the definitive diagnostic test is an analysis of the mutations in the CYP21A2 gene.
|
18574213 |
2008 |
21-hydroxylase deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
After ACTH testing, 13 out of the 32 (41%) cases displayed higher 17-hydroxyprogesterone (17-OHP) levels than normal but less than those found in patients affected by nonclassical adrenal hyperplasia (CAH); these levels were similar to those observed in obligate heterozygotes for CAH due to 21-hydroxylase deficiency (21-OHD).
|
9666866 |
1998 |
21-hydroxylase deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To investigate whether basal and post-ACTH levels of S, DOC, and B and the 21-hydroxylase precursor-to-product ratios determined by tandem mass spectrometry preceded by high-performance liquid chromatography separation (liquid chromatography-tandem mass spectrometry) could disclose distinct profiles in genotypically confirmed classic (no.=14) and non-classic (NC) (no.=18) patients, heterozygote carriers (no.=61) and wildtypes (WT) (no.=27) for 21OHD.
|
20924223 |
2011 |
21-hydroxylase deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
NCAH due to 21-hydroxylase deficiency is diagnosed when the ACTH-stimulated 17-OHP levels > 30 nmol/ l; this threshold varies depending on the assay.
|
17551465 |
2006 |
21-hydroxylase deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
The study was aimed to find out the prevalence of non-classical congenital adrenal hyperplasia (NC-CAH) due to 21-hydroxylase deficiency (21-OHdef) among Greek women with hirsutism and polycystic ovary syndrome (PCOS) and to compare the results of ACTH stimulated 17-hydroxyprogesterone 60 min (17-OHP60) values, with human leukocyte antigens (HLA) phenotypes, in any patient diagnosed as having NC-CAH.
|
18187875 |
2008 |
21-hydroxylase deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A standard dose adrenocorticotropic hormone (ACTH) test revealed an inadequate cortisol response and high 17-hydroxy progesterone levels, suggesting simple virilising congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency.
|
30074481 |
2019 |
21-hydroxylase deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
To determine the cut-off values of basal and post-ACTH serum 17-OHP concentrations, data of patients with suspected 21-OHD has been analysed.
|
12605347 |
2003 |
21-hydroxylase deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Basal blood levels of steroid hormones and serum levels of 17-hydroxyprogesterone at 1 h after intravenous injection of adrenocorticotropic hormone demonstrated that 21-hydroxylase deficiency was not the underlying cause of her virilization.
|
28190856 |
2017 |
21-hydroxylase deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, a normal 17-hydroxyprogesterone response to ACTH stimulation testing does not exclude carrier status for 21-hydroxylase deficiency.
|
9545098 |
1998 |
21-hydroxylase deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to determine whether ACTH-stimulated 17OHP levels in obligate carriers for 21OHD would be correlated with the impairment of the enzyme activity caused by these mutations, which would affect the 17OHP cutoff level for the diagnosis of the NC form.
|
11836321 |
2002 |
21-hydroxylase deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
An exaggerated response of 17- hydroxyprogesterone (17-OHP) to exogenous ACTH stimulation has been found in 30 to 70% of patients with incidentally discovered adrenal tumors, supporting the concept that congenital 21- hydroxylase deficiency may be a predisposing factor for adrenocortical tumorigenesis.
|
17848847 |
2007 |
21-hydroxylase deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
1%) with normal concentrations of 17-OHP after stimulation were found to be carriers of CYP21 gene mutations, indicating low positive predictive values of ACTH stimulation as a screening test for carriers of 21-hydroxylase deficiency.
|
10427156 |
1999 |
21-hydroxylase deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The proband was born with ambiguous genitalia from consanguineous parents and was mistreated as a 21-hydroxylase deficiency case since the age of 5 yr. She had very high levels of plasma ACTH (759 pg/ml or 167 pmol/liter) and high levels of cortisol (28-54 microg/dl or 772-1490 nmol/liter), androstenedione (5-14 ng/ml or 17-48 nmol/liter), T (174-235 ng/dl or 7-8 nmol/liter), and 17-hydroxyprogesterone (8-12 ng/ml or 24-36 nmol/liter).
|
11932321 |
2002 |
21-hydroxylase deficiency
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conclude that the compound heterozygous patients as a group have a significantly higher response of 21-hydroxylase precursors to ACTH stimulation than do patients with the homozygous mild 21-hydroxylase deficiency state.
|
3023431 |
1987 |
21-hydroxylase deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Seven study patients and 8 controls subsequently underwent ACTH stimulation test, and none had levels compatible with a diagnosis of NC-21OHD.
|
19200987 |
2010 |
21-hydroxylase deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mutant P450c21 enzymes carrying specific amino acid substitutions seen in patients with 21-hydroxylase deficiency exhibit activities that correlate with the clinical severity of the disease and with biochemical abnormalities such as 17-hydroxyprogesterone levels after ACTH (corticotropin) stimulation.
|
1958556 |
1991 |
3 beta-Hydroxysteroid dehydrogenase deficiency
|
0.060 |
Biomarker
|
disease |
BEFREE |
Three patients (13%) were diagnosed to have a mild form of 3 beta-hydroxysteroid dehydrogenase deficiency based upon the response of serum delta 5-17-hydroxypregnenolone (delta 5-17P) and dehydroepiandrosterone, and the ratio of delta 5-17P/17-OHP to ACTH stimulation (delta 5-17P: 1543 +/- 272 ng/dl vs. Tanner stage I control subjects, 350 +/- 197 ng/dl; dehydroepiandrosterone: 675 +/- 190 ng/dl vs. Tanner stage I control subjects, 82 +/- 79 ng/dl; delta 5-17P/17-OHP: 8.1 +/- 2.6 vs. Tanner stage I control subjects, 1.4 +/- 0.6).
|
3029158 |
1987 |
3 beta-Hydroxysteroid dehydrogenase deficiency
|
0.060 |
Biomarker
|
disease |
BEFREE |
In conclusion, despite partial gonadal 3 beta HSD deficiency, the dynamics of gonadotropin and gonadal hormone secretion in these siblings indicate the absence of increased LH secretion, in contrast to the markedly increased ACTH secretion resulting from adrenal 3 beta HSD deficiency.(ABSTRACT TRUNCATED AT 400 WORDS)
|
8077318 |
1993 |
3 beta-Hydroxysteroid dehydrogenase deficiency
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
In hyperandrogenic children and women, the pathogenic mechanism of a subtle abnormality in adrenal 3 beta-HSD activity, determined by modestly elevated ACTH stimulated delta-5 steroid levels, which led to the diagnosis of mild nonclassic 3 beta-HSD deficiency in the past, is outside of the type II 3 beta-HSD gene which encodes adrenals and gonads in humans and remains to be further explored.
|
11344940 |
2001 |
3 beta-Hydroxysteroid dehydrogenase deficiency
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Three female patients heterozygotic for severe 3 beta-HSD deficiency CAH with one allele mutation of the gene demonstrated normal ACTH-stimulated hormone profiles.
|
7651769 |
1995 |